Clinical trials: Neoplasms, Solid Tumor
Malignant Solid Tumour
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly.
- Trial name
- NCT00388427
- Testing
- Dasatinib (BMS-354825), Cetuximab (Erbitux, C225)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Pittsburgh
Cancer
BRIDGE-SIC Efficacy Trial
This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians…
- Trial name
- NCT07735442
- Testing
- LLM-generated SIC summary email to clinical teams
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Dana-Farber Cancer Institute
Soft Tissue Sarcoma (STS), Osteosarcoma
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced…
- Trial name
- NCT07648069
- Testing
- Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody, Neoantigen vaccine + anti-PD1 antibody
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Lymphoma
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance…
- Trial name
- NCT03991559
- Testing
- Manganese Chloride, Anti-PD-1 antibody, Systemic therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Advanced Malignancies, Advanced Cancer
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
The purpose of this study was to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a…
- Trial name
- NCT04837196
- Testing
- ASP7517, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumors
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.
- Trial name
- NCT06736327
- Testing
- SKB500
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004173
- Testing
- oxaliplatin, paclitaxel
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
HER-2 Protein Overexpression, HER-2 Gene Amplification
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
HER2 signaling pathway abnormalities or HER2 overexpression can be seen in various types of solid tumors apart from breast cancer or hepatic cancer.
- Trial name
- BIOs-Her (NCT04215159)
- Testing
- Trastuzumab biosimilar, Gemcitabine Hydrochloride, Irinotecan Hydrochloride
- Volunteers
- 42 people
- Sponsor
- Jin-Hee Ahn
Solid Tumor, Immune Response
Clinical Study on Intraluminal Injection of FOLactis
This clinical study is a single arm, prospective, single center clinical study on the safety, tolerability, and preliminary efficacy of a novel FOLactis in situ vaccine in the treatment of advanced solid tumors with malignant…
- Conditions
- Solid Tumor, Immune Response, Pleural Effusion, Malignant, Peritoneal Effusion
- Trial name
- NCT06512896
- Testing
- FOLactis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CT Perfusion and MRI Perfusion in Solid Tumors
PET/MRI Perfusion and CT Perfusion in Solid Tumors
Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor…
- Trial name
- Perfusion (NCT02314962)
- Where
- Switzerland
- Volunteers
- 43 people
- Sponsor
- University of Zurich
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Community Enhanced Virtual Informed Consent
The goal of this clinical trial is to examine perceptions of virtual human communicators and cancer research recruitment messages.
- Trial name
- CEVIC (NCT07805083)
- Testing
- Educational Cancer Intervention, ICF Text Version 1, ICF Text Version 2
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Malignant Melanoma
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma will receive AdCD40L as mono therapy.
- Trial name
- NCT01455259
- Testing
- AdCD40L
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Neoplasms by Histologic Type
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
This dose escalation and dose expansion study is to evaluate and characterize the tolerability, safety, pharmacokinetics and efficacy profile of single agent KY-0118 in Locally Advanced or Metastatic Solid Tumor Patients.
- Trial name
- NCT06175780
- Testing
- KY-0118
- Where
- 8 sites in China
- Volunteers
- 189 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
This is a small phase I study with dose escalation and dose expansion cohorts. The former cohort will need up to 12 subjects with advanced solid tumor to define feasibility and recommended phase 2 dose (RP2D); the latter up to 10…
- Trial name
- NCT03217669
- Testing
- Epacadostat, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Chao Huang
Malignant Solid Tumor, Lymphomas
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
To investigate the dosage of RRx-001 by the subcutaneous route.
- Trial name
- NCT02096341
- Testing
- RRx-001
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- EpicentRx, Inc.
Colorectal Cancer
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer.
- Trial name
- SCI-101 (NCT01110941)
- Testing
- S-1, leucovorin, oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shen Lin
Solid Tumor, Glioblastoma Multiforme
A Trial of Ipatasertib in Combination With Atezolizumab
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B).
- Conditions
- Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
- Trial name
- IceCAP (NCT03673787)
- Testing
- ipatasertib, Atezolizumab
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Solid Cancers
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
This is a translational, open-label, multi-site, prospective cohort study aiming to identify and to monitor immunological biomarkers associated with therapeutic response to immune checkpoints blockade (ICB), in patients with…
- Trial name
- MINER (NCT03514368)
- Testing
- Patients treated with immune checkpoint blockade
- Where
- 3 sites in France
- Volunteers
- 770 people
- Sponsor
- Institut Claudius Regaud
Metastasis, Locally Advanced Solid Tumor
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has selectivity compared with other…
- Conditions
- Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
- Trial name
- NCT05002140
- Testing
- XRD-0394, Palliative radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- XRad Therapeutics Inc
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.